Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 20:6:6.
doi: 10.1186/s40794-020-00107-1. eCollection 2020.

Battling COVID-19: using old weapons for a new enemy

Rohit Kumar  1 , Nitin Gupta  2 , Parul Kodan  3 , Ankit Mittal  1 , Manish Soneja  1 , Naveet Wig  1
Affiliations
Review

Battling COVID-19: using old weapons for a new enemy

Rohit Kumar et al. Trop Dis Travel Med Vaccines. .

Abstract

Coronavirus disease-19 (COVID-19) has reached pandemic proportions. Most of the drugs that are being tried for the treatment have not been evaluated in any randomized controlled trials. The purpose of this review was to summarize the in-vitro and in-vivo efficacy of these drugs on Severe Acute Respiratory Syndrome (SARS-CoV-2) and related viruses (SARS and Middle East Respiratory Syndrome) and evaluate their potential for re-purposing them in the management of COVID-19.

Keywords: Hydroxychloroquine; Lopinavir/ritonavir; Nitazoxanide; Remdisivir; SARS-CoV-2; Tocilizumab.

PubMed Disclaimer

Conflict of interest statement

Competing interestsNone.

Figures

Fig. 1
Fig. 1
Entry and replication of SARS-CoV-2 and the drugs that inhibit the various steps
See this image and copyright information in PMC

References

    1. Zhang X. Epidemiology of Covid-19. N Engl J Med. 2020;27:382. - PubMed
    1. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Muller WJ, O’Horo JC, Shoham S. Infectious diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020. - PMC - PubMed
    1. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949. - PMC - PubMed
    1. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv. 2020;2020.04.10.20060558.
    1. Mahevas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv. 2020;2020.04.10.20060699.

LinkOut - more resources